Navigation Links
Surveyed U.S. and European Neurologists Identify Better Seizure-Free Efficacy as One of the Greatest Unmet Needs in Treating Partial-Onset Seizures in Refractory Epilepsy Patients
Date:6/20/2013

ring improvements in seizure-free efficacy, with 45 percent indicating a high willingness. Payers also indicate receptivity to new products that increase the percentage of adult treatment-refractory patients successfully completing a conversion to monotherapy trial and/or more-effectively reduce partial-onset seizure frequency as an adjunctive therapy in pediatric treatment-refractory patients. However, 30-40 percent of surveyed MCO pharmacy directors would require a 75 percent improvement over lamotrigine immediate release (GlaxoSmithKline/Juste's Lamictal, other brands, generics) on these metrics to consider reimbursement, the highest level of improvement assessed in the report.

"While our findings suggest that most payers will require that a drug deliver a strong clinical performance in these arenas to inspire coverage, they indicate they will accept price premiums under either scenario, although tier-dependent cost controls are likely," said Decision Resources Business Insights Analyst John Crowley, Ph.D. "Moreover, conjoint analysis signals neurologists' own price sensitivity for products that cost considerably more than current second- and third- generation AED brands, which generally fall within a range of $10-15/day in the United States."

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision
'/>"/>

SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. One in Four Surveyed EU5 Physicians Has Been Required to Change a Prescription for Some or Most of Their HIV Patients in the Past Twelve Months, Primarily to Reduce Costs
2. Rising Drug Resistance is Driving Early-Line Use of Powerful Antibiotics Such as Carbapenems for Gram-Negative Infections, According to Surveyed EU5 Physicians
3. For Second- and Subsequent-Line Metastatic Castrate-Resistant Prostate Cancer, Surveyed Oncologists Indicate that Improved Symptom Control and Quality of Life is one of the Greatest Unmet Needs
4. For Chronic Obstructive Pulmonary Disease, Surveyed Pulmonologists Indicate That Improved Effect on Quality of Life is One of the Greatest Unmet Needs
5. The Majority of Surveyed Gastroenterologists in the EU5 Identify Remicade as Their Most Preferred Biologic for the Treatment of Ulcerative Colitis
6. For Treating Clostridium difficile Infections, Surveyed Infectious Disease Specialists Agree That Effect on Recurrence Rate is One of the Drug Attributes that Most Influences Their Prescribing Decisions
7. Surveyed U.S. Pulmonologists Expect to Treat Nearly 50 Percent of Their Severe, Refractory Asthma Patients With a Biologic or Biosimilar Version of Xolair By the End of 2018
8. Surveyed U.S. Neurologists Would Prescribe Biogen Idecs Tecfidera to 20 Percent of Their Patients with Relapsing-Remitting Multiple Sclerosis (RR-MS)
9. Surveyed U.S. Physicians Indicate That Xarelto and Apixaban Will Benefit From the Lack of Use of a Fast-Acting Injectable Anticoagulant in the Treatment and Secondary Prophylaxis of Deep Vein Thrombosis/Pulmonary Embolism
10. Despite the Recent Availability of Xtandi, Zytiga Continues to Dominate the Second-Line Metastatic Castrate-Resistant Prostate Cancer Setting, According to Surveyed U.S. Oncologists and Urologists
11. Surveyed U.S. and European Neurologists Agree that a Therapys Effect on Physical Disability is the Most Important Attribute Influencing Prescribing Decisions in Secondary-Progressive Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Calif. , Aug. 31, 2015 ... flow cytometry is experiencing a rise in active ... demand in underdeveloped nations to quantitate CD4 cell ... Logo - http://photos.prnewswire.com/prnh/20150831/262206LOGO ... of the Global Flow Cytometry Market ( http://www.frost.com/nf0e ...
(Date:8/31/2015)... , Aug. 31, 2015  The departments of Drug ... today at Gaudenzia Concept 90 to raise awareness for ... crisis in Pennsylvania and help ... focus on recovery through the Building Bridges to ... are dying every day to a disease that is ...
(Date:8/31/2015)... , Aug. 31, 2015  Diplomat Pharmacy, Inc. (NYSE: ... that Phil Hagerman , Chairman & CEO, and ... conferences. Mr. Hagerman and Mr. Whelan are ... in Boston on Wednesday, September 9, ... Mr. Whelan are also scheduled to participate in the Robert ...
Breaking Medicine Technology:Clinical Applications of Flow Cytometry Instrumentation and Reagents are Transforming this Market with a High-Growth Path 2Clinical Applications of Flow Cytometry Instrumentation and Reagents are Transforming this Market with a High-Growth Path 3Clinical Applications of Flow Cytometry Instrumentation and Reagents are Transforming this Market with a High-Growth Path 4Pennsylvania Departments of Drug & Alcohol Programs and Health Kick-off Second Annual Building Bridges to Recovery Initiative 2Diplomat to Participate in Upcoming Investor Conferences 2
... OrbusNeich today announced that six-month clinical follow-up data show the safety ... balloon (Sequent Please®, B.Braun) followed by implantation of the company,s Genous ... , , , ... investigator-initiated, single center, all-comers POTENT ( P aclitaxel-eluting ball O on ...
... Pfizer Inc. (NYSE: PFE ) announced today that based ... be discontinuing commercial availability of Mylotarg® (gemtuzumab ozogamicin for Injection) (used for ... States and that it will be voluntarily withdrawing the new drug ... , , ...
Cached Medicine Technology:Data Show OrbusNeich's Genous™ Bio-engineered R stent™ is Safe and Effective in Combination with Drug-Eluting Balloon 2Data Show OrbusNeich's Genous™ Bio-engineered R stent™ is Safe and Effective in Combination with Drug-Eluting Balloon 3Pfizer Prepares for Voluntary Withdrawal of U.S. New Drug Application and for Discontinuation of Commercial Availability of Mylotarg® 2Pfizer Prepares for Voluntary Withdrawal of U.S. New Drug Application and for Discontinuation of Commercial Availability of Mylotarg® 3Pfizer Prepares for Voluntary Withdrawal of U.S. New Drug Application and for Discontinuation of Commercial Availability of Mylotarg® 4Pfizer Prepares for Voluntary Withdrawal of U.S. New Drug Application and for Discontinuation of Commercial Availability of Mylotarg® 5Pfizer Prepares for Voluntary Withdrawal of U.S. New Drug Application and for Discontinuation of Commercial Availability of Mylotarg® 6
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... In an ... from the Plastic and Reconstructive Surgery Global Open Journal that discusses the future of ... article discussed how, in the future, customized implants, prosthetics, and other 3-D printed tools ...
(Date:8/31/2015)... ... August 31, 2015 , ... David L. Chalnick, M.D., ... of the first doctors in the area to perform minimally invasive hip replacement ... impressive: faster recovery, decreased immediate and long-term pain, and an accelerated return to ...
(Date:8/31/2015)... Scotch Plains, NJ (PRWEB) , ... August 31, 2015 , ... ... years as an “NJ Top Doc.” , At OSSMC, Dr. Kovatis treats all surgical ... general orthopedics and traumatic injuries to the entire musculoskeletal system, excluding the spine. , ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... diagnostic services, and others—to hold down costs? , In a commentary for ... of HealthReveal, presents the concept of “clinical efficacy,” which would bind parties together ...
(Date:8/31/2015)... CA (PRWEB) , ... August 31, 2015 , ... ... the 2015 ABBY Awards, at the 16th Innovations in Healthcare(SM) Awards Event ... Adaptive Business Leaders (ABL) Organization , recognizes innovative organizations and individuals who ...
Breaking Medicine News(10 mins):Health News:Recent Article on 3-D Printing Highlights the Future of Custom Medical Solutions Using the Technology, says Beverly Hills Physicians 2Health News:Recent Article on 3-D Printing Highlights the Future of Custom Medical Solutions Using the Technology, says Beverly Hills Physicians 3Health News:NJ Top Docs Presents, Dr. David L. Chalnick! 2Health News:NJ Top Docs Presents, Dr. David L. Chalnick! 3Health News:NJ Top Docs Presents, Dr. David L. Chalnick! 4Health News:NJ Top Docs Presents, Dr. Paul Kovatis of Orthopedic Spine & Sports Medicine Center on his Five Year Anniversary as an "NJ Top Doc" 2Health News:How “Clinical Efficacy” Can Rein in Healthcare Costs 2Health News:How “Clinical Efficacy” Can Rein in Healthcare Costs 3Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 2Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 3Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 4Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 5Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 6Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 7Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 8
... 2 Rochester Medical Corporation (Nasdaq: ROCM ) ... 31, 2008.The Company reported sales of $8,436,000 for the current ... year. It also reported net income of $54,000 or ... or $.02 per diluted share for the first quarter of ...
... Calif., Feb. 2 Digirad Corporation (Nasdaq: ... and personnel and equipment leasing services that improve patient ... it has sold the assets related to three northern ... with Rancho Santa Fe, Calif.-based MD Office Solutions calls ...
... More exposure meant more symptoms, study found , , MONDAY, ... hours watching television are at higher risk for depression ... significantly greater odds of being depressed seven years later, ... television viewed, according to a report involving more than ...
... for Quality,Assurance (NCQA) has awarded Unison Health Plan of ... program through December 2011. The plan serves,more than ... is based on how well a health plan ensures ... the health,plan,s core systems and processes, but also the ...
... are heavy users of marijuana are more likely ... to a new study. Pediatric researchers found abnormalities ... regions involved in memory, attention, decision-making, language and ... concern because adolescence is a crucial period for ...
... Post-Katrina flooded homes may contain harmful levels of ... mold films, and aerosols may also have exposed residents, ... without the need for direct skin contact, according to ... (Volume 26, Number 3) of Environmental Engineering Science, a ...
Cached Medicine News:Health News:Rochester Medical Reports First Quarter Results 2Health News:Rochester Medical Reports First Quarter Results 3Health News:Rochester Medical Reports First Quarter Results 4Health News:Rochester Medical Reports First Quarter Results 5Health News:Rochester Medical Reports First Quarter Results 6Health News:Rochester Medical Reports First Quarter Results 7Health News:Rochester Medical Reports First Quarter Results 8Health News:Digirad Corporation Sells Northern California Service Hubs 2Health News:Teen TV Time Tied to Adult Depression 2Health News:Teen TV Time Tied to Adult Depression 3Health News:Unison Health Plan of Ohio Accredited by NCQA 2Health News:Heavy marijuana use may damage developing brain in teens, young adults 2Health News:Newly Described Contaminant Sources in Katrina-Flooded Homes Pose Health Risks 2
... When myocardial infarction is suspected, ... sensitive rapid assay allows rapid ... troponin T from a single ... result is available within minutes ...
The Polygraf ID multi-parametric recorder works with POLYGRAM NET analysis software to create a unique interface that combines web-style navigation, graphical presentation and intuitive design to del...
... the industry standard high intensity 300 Watt Xenon ... price. A universal turret on the front panel ... Olympus, Storz, ACMI/Circon and Wolf cable connectors., ,Front ... timer. The White Sun will quickly illuminate at ...
... is intended for determination of human NGAL ... tissue extracts or culture media., NGAL (neutrophil ... urine, as early as 2 hours after ... processes. NGAL expression in plasma or urine ...
Medicine Products: